Tag:

Sanofi

Latest Headlines

Latest Headlines

Sanofi continues pediatric vaccine push with FDA Quadracel nod

Sanofi Pasteur counts pediatric vaccines among its 5 key areas, and it's bolstering its offerings in the field with Wednesday's FDA approval of the Quadracel vaccine.

Opdivo, Praluent and LCZ-696 top a launch crop poised for $27B in sales

What's better than a new drug launch? A launch destined for greatness, of course. For sales and marketing teams, that's about as much job security as you can get. 

Sanofi aims for that sweet smell of success with spring Nasacort campaign

Sanofi is hoping to spring forward with a new marketing campaign for OTC Nasacort.

Sanofi finally unloads an embattled R&D site in $270M Evotec deal

Sanofi is shipping more than 200 researchers to German outsourcing firm Evotec as it finally gets out of a French R&D site whose fate led to a squabble with the local government, reaching a compromise the company believes will leave all sides appeased.

Sanofi's Shantha prepared to deliver 37M doses of long-delayed pediatric vaccine

Sanofi's Indian affiliate, Shantha Biotechnics, says it's ready to deliver 37 million doses of its low-cost pediatric pentavalent vaccine, Shan5.

Sanofi's diabetes franchise one step closer to U.S. Lyxumia launch

Sanofi can go back to the FDA with Lyxumia. The French drugmaker got good news from a cardiovascular outcomes study, required by the FDA before it would approve the diabetes drug.

R&D exec Tal Zaks leaps from flagging Sanofi to fast-growing Moderna

While a long list of biopharma companies have been dropping the ax on R&D staffers in recent weeks and months, some of the top execs being shown the exit are finding that new doors are opening as fast as old positions are whisked away. Today, Tal Zaks underscored the bright side of restructuring, being named chief medical officer at Moderna Therapeutics a month after he was among 100 oncology R&D staffers who were ushered out at Sanofi in a recent reorganization.

Amgen scores a victory for PCSK9, halving cardio risks after one year

A new generation of cardiovascular drugs has proved itself capable of lowering bad cholesterol across dozens of Phase III trials, but many physicians are holding out to see whether doing so can meaningfully improve patients' lives. In an early peek at some long-term data, one such injected therapy from Amgen halved the risk of major cardiovascular problems after one year of treatment, bolstering the case for the whole class of drugs.

Sanofi backs pitch to turn Marseille into an immunotherapy R&D hub

The French city of Marseille has staked its claim for a corner of the booming immunotherapy R&D ecosystem. And the plan has some big-name backers, with Sanofi and Innate Pharma both signing up as founders of the MI-mAbs immunotherapy research center in the city.

UPDATED: Goldman cuts Afrezza sales forecast in half on slow uptake, pricing pressure

Pharma watchers have been tracking the launch of MannKind's Afrezza like other people track batting averages or Oscar buzz. Unfortunately for fans of the inhaled insulin, early numbers don't look good. So much so that Goldman Sachs downgraded MannKind's stock and cut its peak sales projection in half.